Phio Pharmaceuticals names new independent director
3 May 2022 -

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a US-based clinical stage biotechnology company, announced on Monday that it has named Patricia A Bradford as its new independent director.

Bradford has over four decades of executive HR experience and a financial acumen having received CPA accreditation during her time at Deloitte. She has held various roles of increasing responsibility at Unisys Corporation. She has worked at Deloitte, in positions in the Audit and Tax departments. Presently, Bradford offers HR consulting services to a wide range of companies, concentrating on offering individual coaching for senior executives and high potential employees recommended by management.

Robert Bitterman, Phio Pharmaceuticals chairman, said, 'We are delighted to welcome Patricia to the Phio board. I am certain that her wealth of experience as an executive at rapidly growing international conglomerates and in HR management will bring tremendous value to the Board. We believe that Patricia will be an effective steward of the company and counsellor to the management team.'